Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
Braz. J. Pharm. Sci. (Online)
;
53(1): e16102, 2017. tab, graf
Article
in English
| LILACS, SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-839466
ABSTRACT
ABSTRACT Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Anxiety
/
Cholesterol
/
Simvastatin
Limits:
Animals
Language:
English
Journal:
Braz. J. Pharm. Sci. (Online)
Year:
2017
Type:
Article
Institution/Affiliation country:
Instituto Dante Pazzanese de Cardiologia/BR
/
Universidade Regional de Blumenau/BR
/
Universidade da Região de Joinville/BR
Similar
MEDLINE
...
LILACS
LIS